A Novel Screening System for Claudin Binder Using Baculoviral Display by Kakutani, Hideki et al.
A Novel Screening System for Claudin Binder Using
Baculoviral Display
Hideki Kakutani
1., Azusa Takahashi
1., Masuo Kondoh
1*, Yumiko Saito
1, Toshiaki Yamaura
1, Toshiko
Sakihama
2, Takao Hamakubo
2, Kiyohito Yagi
1*
1Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan, 2Department of Molecular
Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Meguro, Tokyo, Japan
Abstract
Recent progress in cell biology has provided new insight into the claudin (CL) family of integral membrane proteins, which
contains more than 20 members, as a target for pharmaceutical therapy. Few ligands for CL have been identified because it
is difficult to prepare CL in an intact form. In the present study, we developed a method to screen for CL binders by using
the budded baculovirus (BV) display system. CL4-displaying BV interacted with a CL4 binder, the C-terminal fragment of
Clostridium perfringens enterotoxin (C-CPE), but it did not interact with C-CPE that was mutated in its CL4-binding region. C-
CPE did not interact with BV and CL1-displaying BV. We used CL4-displaying BV to select CL4-binding phage in a mixture of
a scFv-phage and C-CPE-phage. The percentage of C-CPE-phage in the phage mixture increased from 16.7% before
selection to 92% after selection, indicating that CL-displaying BV may be useful for the selection of CL binders. We prepared
a C-CPE phage library by mutating the functional amino acids. We screened the library for CL4 binders by affinity to CL4-
displaying BV, and we found that the novel CL4 binders modulated the tight-junction barrier. These findings indicate that
the CL-displaying BV system may be a promising method to produce a novel CL binder and modulator.
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Introduction
Tight junctions (TJ) are intercellular adhesion complexes in
epithelial and endothelial cells; TJs are located in the most apical
part of the complexes [1]. TJs have a barrier function and a fence
function [2–4]. TJs contribute to epithelial and endothelial barrier
functions by restricting the diffusion of solutes through the
paracellular pathway. TJs maintain cellular polarity by preventing
the free movement of membrane proteins between the apical and
basal membranes [5]. Loss of cell-cell adhesion and cellular
polarity commonly occurs in the early stages of cancer [6].
Modulation of the TJ barrier function can be a method to enhance
drug absorption, and TJ components exposed on the surface of
cancer cells can be a target for cancer therapy.
Biochemical analyses of TJs have identified TJ components,
such as occludin, claudins (CLs) and junction adhesion molecule
[7]. The CL family contains more than 20 integral tetra-
transmembrane proteins that play pivotal roles in the TJ barrier
and fence functions. CL1-deficient mice lack the epidermal
barrier, while CL5-deficient mice lack the blood-brain barrier
[8,9], indicating that the regulation of the TJ barrier by
modulation of CLs may be a promising method for drug delivery.
Clostridium perfringens enterotoxin (CPE) causes food poisoning in
humans [10]. An interaction between the C-terminal domain of
CPE (C-CPE) with CL4 deregulates the TJ barrier [11,12]. We
previously found that C-CPE enhances jejunal absorption through
its interaction with CL4, indicating that a CL binder is a potent
drug-delivery system [13].
The majority of lethal cancers are derived from epithelial tissues
[14]. Malignant tumor cells frequently exhibit abnormal TJ
function, followed by the deregulation of cellular polarity and
intercellular contact, which is commonly observed in both
advanced tumors and the early stages of carcinogenesis [6]. Some
CLs are overexpressed in various types of cancers. For example,
CL3 and CL4 are overexpressed in breast, prostate, ovarian,
pancreatic and gastric cancers. CL1, CL7, CL10 and CL16 are
overexpressed in colon, gastric, thyroid and ovarian cancers,
respectively [15,16]. These findings indicate that the CLs may be a
target molecule for cancer therapy. A receptor for CPE is CL4
[11,12]. CPE has anti-tumor activity against human pancreatic
and ovarian cancers without side effects [17,18]. The CLs binders
will be useful for cancer-targeting therapy.
As above, recent investigations of CLs provide new insight into
their use as pharmaceutical agents; for example, a CL binder may
be used in drug delivery and anti-tumor therapy. Selection of a CL
binder by using a recombinant CL protein is a putative method to
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proteins with high hydrophobicity; there has been little success in
the preparation of intact CL protein. Recently, a novel type of
protein expression system that uses baculovirus has been
developed. Membrane proteins are displayed on the budded
baculovirus (BV) in their active form [19–21], indicating that the
BV system may be useful for the preparation of a CL binder. In
the present study, we investigated whether a CL binder was
screened by using a CL-displaying BV.
Results
Preparation of CL4-displaying BV
C-CPE is the only known CL binder and modulator [12,13,22].
C-CPE has affinity to CL4 in a nanomolar range [23]. We chose
C-CPE and CL4 as models of the CL binder and CL, respectively.
Several reports indicate that membrane proteins expressed on the
surface of BV are in an intact form [19–21]. To check the
expression of CL4 on the BV, we performed immunoblot analysis
of the lysate of CL4-BV against CL4. As shown in Fig. 1A, CL4
was detected in the virus lysates. To determine if the CL4
expressed on the virus has an intact form, we performed enzyme-
linked immunosorbent assay (ELISA) with CL4-BV-coated
immunoplates. C-CPE binds to the extracellular loop domain of
CL4 [23]. After the addition of C-CPE to the CL4-BV-coated
plate, the C-CPE bound to the CL4-BV-coated plate was detected
by anti-his-tag antibody, followed by incubation with horseradish
peroxidase-labeled antibody. C-CPE was dose-dependently bound
to CL4-BV, whereas C-CPE did not interact with wild-BV
(Fig. 1B). Deletion of the CL4-binding region (C-CPE303)
attenuated the interaction of C-CPE with CL4-BV (Fig. 1C).
Together, these results indicate that the CL4 displayed on BV may
have an intact extracellular loop region.
Selection of C-CPE-phage by using CL4-BV
We next examined the interaction between C-CPE-phage and
CL4-BV. As shown in Fig. 2A, C-CPE-phage bound to CL4-BV
but not to wild-BV, and a scFv-phage did not bind to CL4-BV. To
determine if CL-BV can be used to select CL binders, we prepared
a mixture of C-CPE-phage and scFv-phage at a ratio of 2:10 and
used CL4-BV to select CL4-binding phage in the mixtures. The
amount of C-CPE-phage was increased to 11 of 12 clones in the
mixture (Fig. 2B), indicating that CL-BV may be useful in the
preparation of CL binders.
We previously found that each substitution of S304, S305, S307,
N309, S313 and K318 with alanine increased the binding of C-
CPE to CL4 [24]. Here, we prepared a phage library for C-CPE
by randomly changing the functional 6 amino acids to any of the
20 amino acids. To confirm the diversity of the library, we checked
the sequences of 17 randomly isolated clones. Each of the 17
clones had a different sequence, indicating that the library has a
diverse population of C-CPE mutants (Table 1).
Then, we screened the CL4-binding phage by their affinity to
CL4-BV. After addition of the C-CPE library to CL4-BV-
adsorbed tubes, the CL4-BV-bound phages were recovered (1
st
screening). We repeated this screening process two more times (2
nd
screening and 3
rd screening). If the number of CL4-bound phage is
increased during the screening, the ratio of the incubated phage
titers to the recovered phage titers will increase. As shown in
Fig. 3A, the ratio was increased during screening from 4.5610
27
to 5.5610
25, indicating that the screening system for CL4 binders
may work. Indeed, the number of monoclonal phage clones with
high affinity to CL4-BV was increased after the 3
rd screening
compared with that after the 2
nd screening (Fig. 3B).
We analyzed the sequences of the CL4-BV-bound phages and
got novel CL4-binder candidates with amino acid sequences that
differed from the wild-type sequence (Table 2). To investigate their
CL4-binding, we prepared the recombinant proteins of the
binders and investigated their interaction with CL4 by ELISA
with CL-BVs. As shown in Fig. 4A, the novel C-CPE derivatives
had affinity to CL4 but not CL1. Next, we investigated whether
the novel CL4 binders modulate TJ barrier in Caco-2 monolayer
cell sheets, a popular model for the evaluation of TJ barriers [25].
Figure 1. Preparation of CL4-displaying BV. A) Immunoblot
analysis. Wild-BV and CL4-BV (0.1 mg/lane) were subjected to SDS-PAGE,
followed by immunoblot analysis with anti-CL4 antibody. The lysate of
CL4-expressing L (CL4/L) cells was used as a positive control. B, C)
Interaction of a CL4 binder with CL4-BV. Immunotubes were coated
with the wild-BV or CL4-BV, and C-CPE (B) or mutated C-CPE (C) was
added to the BV-coated immunotubes at the indicated concentration.
C-CPE bound to the BV-coated tubes was detected by ELISA with an
anti-his-tag antibody.
doi:10.1371/journal.pone.0016611.g001
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transepithelial electrical resistance (TEER) values, a marker of
TJ integrity, and the TEER values increased after removal of C-
CPE. The C-CPE derivatives (clones 1–5) had TJ-modulating
activity similar to that of C-CPE (Fig. 4B).
Discussion
CL is a promising target for pharmaceutical therapy. However,
CL has low antigenicity, and there has been little success in the
preparation of monoclonal antibody against the extracellular loop
region of CL. The three-dimensional structure of CL has never
been determined, so it is impossible to perform a theoretical design
of a CL binder based on the structural information. In the present
study, we developed a novel screening system for CL binders by
using a BV system and a C-CPE phage display library, and we
used this system to identify novel CL4 binders.
In ligand screening, the preparation of a receptor for the ligand
is very critical. Membrane proteins are especially difficult to
prepare as recombinant protein with an intact structure.
Functional membrane proteins such as cell-surface proteins are
heterologously expressed on BV in their native forms [19–21].
Interactions between membrane proteins can be detected by using
receptor-displaying and ligand-displaying BV [21]. In the present
report, we found that CL4-BV interacts with a CL4 binder, C-
CPE, but it does not interact with C-CPE303 that lacks the CL4-
binding residues of C-CPE. The CL4-binding site of C-CPE
corresponds to that of CPE; so, the second extracellular loop of CL
appears to be the C-CPE-binding site [23,26]. These findings
indicate that CL4 displayed on BV may have native form. We
anticipate that CL-BV will be useful for the preparation of CL
binders, such as peptides and antibodies.
To the best of our knowledge, the preparation of CL binder has
been performed by only four groups. Offner et al. prepared
polyclonal antibodies against extracellular domains of CL3 and
CL4 [27], Ling et al. screened peptide types of CL4 binder by
using a 12-mer peptide phage display library and CL4-expressing
cells [28], Suzuki et al. generated a monoclonal antibody against
the second extracellular loop of CL4 from mice immunized with a
human pancreatic cancer cell line [29] and Romani et al. screened
scFv against CL3 by using a human antibody phage display library
[30]. However, the CL modulators have never been developed;
thus, C-CPE is the only known CL4 modulator [12]. In the
present study, we prepared a C-CPE phage library containing C-
CPE mutants in which each of the 6 functional amino acids was
randomly replaced with an amino acid, and we isolated CL4
binders by using CL4-BV as a screening ligand. Interestingly, all of
Figure 2. Selection of C-CPE-displaying phage by using the
CL4-BV system. A) Interaction of C-CPE-displaying phage with CL4-BV.
Wild-BV or CL4-BV was coated on an immunoplate, and then scFv-
displaying phage or C-CPE-displaying phage was added to the BV-
coated immunoplate at the indicated concentrations. The BV-bound
phages were detected by ELISA with anti-M13 antibody as described in
Materials and methods. Data are representative of two independent
experiments. Data are means 6 SD (n=3). B) Enrichment of C-CPE-
displaying phage by the BV system. A mixture of scFv-phage and C-CPE-
phage (mixing ratio of scFv-phage to C-CPE-phage=2:10) was
incubated with a CL4-BV-coated immunotube, and the bound phages
were recovered. Each phage clone was identified by PCR amplification,
followed by agarose gel electrophoresis. Upper and lower pictures are
before and after the selection, respectively. The putative sizes of the
PCR products are 856 and 523 bp in scFv and C-CPE, respectively. The
data are representative of two independent experiments.
doi:10.1371/journal.pone.0016611.g002
Table 1. C-CPE phage library.
304 305 307 309 313 318
C-CPE S S S N S K
Clone 1 V T C V N K
2C P A H L T
3A G G V P P
4R G H L E H
5A A P S R Q
6P A P D P A
7 CTTTNK
8H P S P G H
9R G G R N R
10 A P S T Q P
11 V L G N M R
12 P P A T F R
13 G D C S N L
14 F R V F R N
15 S Q Q W T T
16 S R L E W Q
17 K R E R Q S
Phage clones were randomly picked up from the C-CPE phage library, and the
amino acids sequences of C-CPE mutant were analyzed.
doi:10.1371/journal.pone.0016611.t001
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the substitution of the amino acids with the other amino acids
modulated CL4. These findings indicate that a BV screening
system with a C-CPE library may be a powerful method to
develop CL modulators.
The CL family forms various types of TJ barriers through
combinations of its more than 20 members in homophilic/
heterophilic CL strands [31,32]. Intercellular proteins ZO-1 and
ZO-2 determine the localization of CL strands [33]. If a screening
system to reconstitute heterogeneous CL strands with ZO-1 and/
or ZO-2 is developed, then useful and effective CL modulators can
be identified. In this point, the BV system has extremely superior
features. G protein and G protein-coupled receptors have been
Figure 3. Screening of a novel CL4 binder. A) Enrichment of
phages with affinity to CL4-BV. CL4-BVs coated on immunotubes were
incubated with the C-CPE-derivative phage library at 1.6610
12 CFU titer
(1
st input phage). The phages bound to CL4-BV were recovered (1
st
output phage). The CL4-BV-binding phages were subjected to two
additional cycles of the incubation and wash step, resulting in 2
nd,3
rd
output phage. The ratio of output phage to input phage titers was
calculated. B) Monoclonal analysis of C-CPE-derivative phage. CL4-BV-
bound phage clones were isolated from the 2
nd and 3
rd output phages,
and the interaction of the monoclonal phage with CL4-BV was
examined by ELISA with anti-M13 antibody as described in Materials
and methods. Data are expressed as relative binding to that of C-CPE-
phage indicated by the most right column.
doi:10.1371/journal.pone.0016611.g003
Table 2. CL4-binding phages.
304 305 307 309 313 318
C-CPE S S S N S K
Clone 1 R V S A R R
2R S V A R K
3GDGR T R
4S A P R S A
5R S L K S K
The sequences of C-CPE mutant in the CL4-binding phages were analyzed.
doi:10.1371/journal.pone.0016611.t002
Figure 4. Isolation of a novel CL4 modulator. A) Interaction of the
C-CPE derivatives with CL4. C-CPE derivatives were prepared as his-
tagged recombinant proteins. The C-CPE derivatives (0.02 mg) were
added to CL-BV-coated immunoplates, followed by detection of the C-
CPE derivatives bound to CL-BV. Data are means 6 SD (n=4). B)
Modulation of tight junction-barriers. Caco-2 cells were cultured on
Transwell
TM chambers. When TEER values reach a plateau, the cells were
treated with C-CPE or C-CPE derivatives at the indicated concentrations.
After 18 h of exposure to the C-CPEs, the cells were washed with
medium to remove C-CPEs, and then the cells were cultured for an
additional 24 h. Changes in TEER values were monitored during the C-
CPEs treatment. Relative TEER values were calculated as the ratio of
TEER values at 0 h. Data are representative of two independent
experiments. The data are means 6 SD (n=4).
doi:10.1371/journal.pone.0016611.g004
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secretase complexes have also been reconstituted on BV [35]. In
the near future, the reconstituted CL system on BV will be
developed and used for the screening of CL binders and
modulators, hopefully leading to breakthroughs in pharmaceutical
therapies that target CLs.
Materials and Methods
Recombinant BV construction and Sf9 cell culture
Recombinant BV was prepared by using the Bac-to-Bac
expression system, according to the manufacturer’s instructions
(Invitrogen, Gaithersburg, MD). Briefly, mouse CL1 and CL4
cDNA (kind gifts from Dr. M Furuse, Kobe University, Japan)
were inserted into pFastBac1, and the resulting plasmids were
transduced into DH10Bac E. Coli cells. Recombinant bacmid
DNA was extracted from the cells. Sf9 cells were transduced with
the bacmid coding CL, and the recombinant BV was recovered by
centrifugation of the conditioned medium [36].
Preparation of the BV fractions
Sf9 cells (2610
6 cells) were infected with recombinant BV at a
multiplicity of infection of 5. Seventy-two hours after infection, the
BV fraction was recovered from the culture supernatant of
infected Sf9 cells by centrifugation. The pellets of the BV fraction
were resuspended in Tris-buffered saline (TBS) containing 1%
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and
then stored at 4uC until use. The expression of CL1 and CL4 in
the BV was confirmed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and immunoblot analysis with
anti-CL antibodies (Zymed Laboratory, South San Francisco,
CA).
Preparation of mutant C-CPE library
C-CPE fragments in which the functional amino acids (S304, S305,
S307, N309, S313 and K318) [24] were randomly mutated were
prepared by polymerase chain reaction (PCR) with pET-H10PER as a
template, a forward primer (59-catgccatggccgatatagaaaaagaaatccttgatt-
tagctgctg-39, Nco I site is underlined) and a reverse primer (59-
ttttccttttgcggccgcaaasnnttgaaataatatsnnataagggtasnntccsnnatasnnsnnat-
tagcttt-39, Not I site is underlined, and the randomly mutated amino
acids are in italics). The PCR fragments were inserted into a pY03
phagemid at the NcoI/NotI sites [22]. The resultant phagemid
containing the C-CPE mutant library was transduced into E. coli TG1
cells, and then the cells were stored at 280uC.
Preparation of phage
TG1 cells containing phagemid coding a scFv, C-CPE, C-CPE
mutant or C-CPE mutant library were culture in 2YT medium
containing 2% glucose and ampicillin. When the cells grew to a
growing phage, M13K07 helper phages (Invitrogen) were added,
and the medium was changed into 2YT medium containing
ampicillin and kanamycin. After an additional 6 h of culture, the
phages in the conditioned medium were precipitated with
polyethylene glycol. The phages were suspended in phosphate-
buffered saline (PBS) and stored at 4uC until use.
ELISA
Wild-BVs or CL-BVs (0.5 mg/well) were adsorbed onto an
immunoplate (Greiner Bio-One, Frickenhausen, Germany). The
wells were washed with PBS and blocked with TBS containing
1.6% BlockAce (Dainippon Sumitomo Pharma, Osaka, Japan). C-
CPEs or phages were incubated in the immunoplate, and the BV-
bound C-CPEs or phages were detected by using anti-his-tag
antibody (Novagen, Darmstadt, Germany) or anti-M13 antibody
(Amersham-Pharmacia Biotech, Uppsala, Sweden), respectively,
horseradish peroxidase-labelled secondary antibody and TMB
peroxidase substrate (Nacalai Tesque, Kyoto, Japan). The
immunoreactive C-CPEs or phages were quantified by the
measurement of absorbance at 450 nm. In the screening of
phages, the data were normalized by the amounts of phages,
which were quantified by ELISA for the FLAG-tag contained in
the coat protein.
Selection of phage by using BV
A total of 0.5 mg of BV was adsorbed onto an immunotube
(Nunc, Roskilde, Denmark). The tube was washed with PBS and
blocked with TBS containing 4.0% BlockAce. The BV-coated
tubes were incubated with mixture of phages, and then the tubes
were washed 15 times with PBS and 15 times with PBS containing
0.05% Tween 20. The phages bound to the tube were eluted with
100 mM HCl. TG1 cells were infected with the eluted phages, and
phages were prepared as described above. The resulting phages
were subjected to repeated selection by using the BV-coated
immunotubes.
Identification of a phage clone
To identify an isolated phage clone, we performed PCR or
sequencing analysis. We amplified the inserted fragment into the
phagemid by PCR using forward primer 59-caggaaacagctatgac-39
and reverse primer 59-gtaaatgaattttctgtatgagg-39. The resultant
PCR products were subjected to agarose gel electrophoresis
followed by staining with ethidium bromide. We performed a
sequence analysis with primer 59-gtaaatgaattttctgtatgagg-39.
Measurement of phage titer
To quantify the concentration of phages, we measured the titer
(colony formation unit (CFU)/ml) of the phage solution. Briefly,
the phage solution was diluted to 10
25–10
210 with PBS. The
diluted solution was seeded onto Petrifilm
TM (Tech-Jam, Osaka,
Japan). After 24 h of incubation, the colonies were counted, and
the titer was calculated.
Purification of C-CPE mutants
C-CPE and C-CPE303, in which the CL-4 binding region of
C-CPE was deleted, were prepared as described previously [13].
To prepare plasmid containing C-CPE mutants, the C-CPE
mutant fragment was PCR-amplified by using phagemids coding
C-CPE mutants as a template. The resulting PCR fragment was
inserted into pET16b, and the sequence was confirmed. The
plasmids were transduced into E. coli strain BL21 (DE3), and
production of mutant C-CPEs was induced by the addition of
isopropyl-D-thiogalactopyranoside. The harvested cells were
lysed in buffer A (10 mM Tris-HCl, pH 8.0, 400 mM NaCl,
5m MM g C l 2, 0.1 mM phenylmethanesulfonyl fluoride, 1 mM
2-mercaptoethanol, and 10% glycerol) that was supplemented
with 8 M urea when necessary. The lysates were applied to
HiTrap
TM Chelating HP (GE Healthcare, Buckinghamshire,
UK), and mutant C-CPEs were eluted with buffer A containing
100–400 mM imidazole. The buffer was exchanged with PBS by
using a PD-10 column (GE Healthcare), and the purified protein
was stored at 280uC until use. Purification of the mutant C-
CPEs was confirmed by SDS-PAGE, followed by staining with
Coomassie Brilliant Blue and by immunoblotting with anti-his-
tag antibody (Novagen). Protein was quantified by using a BCA
protein assay kit with bovine serum albumin as a standard (Pierce
Chemical, Rockford, IL).
Screening of Claudin Binders
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Caco-2 cells were seeded in Transwell
TM chambers (Corning,
NY) at a subconfluent density. The TEER of the Caco-2
monolayer cell sheets on the chamber was monitored by using a
Millicell-ERS epithelial volt-ohmmeter (Millipore, Billerica, MA).
When TEER values reached a plateau, indicating that TJs were
well-developed in the cell sheets, the Caco-2 monolayers were
treated with C-CPE or C-CPE mutants on the basal side of the
chamber. Changes in TEER values were monitored. The TEER
values were normalized by the area of the Caco-2 monolayer, and
the TEER value of a blank Transwell
TM chamber (background)
was subtracted.
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